anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

223,861-223,920 of 319,975

filter-aware
02
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
03
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
04
The slide highlights clinical validation through trial count and patient numbers, alongside key product attributes.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Problem1 hit
05
The slide uses a Gantt-style visualization to show the status of multiple clinical trials.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Problem1 hit
06
Uses a process diagram to show the transition from cold to hot tumor states.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
07
The central diagram illustrates the mechanism of action, contrasting 'Absence of Effector T Cells' (Platinum resistant) with 'Presence of Effector T Cells' (Platinum sensitive).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
08
Uses a pyramid diagram to represent the progression of clinical validation.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
09
The slide compares mPFS results against SOC-AURELIA and ELAHARE benchmarks.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
10
The slide outlines the methodology and validation of a clinical trial.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
11
The slide uses a table to compare clinical outcomes across patient subgroups (all, resistant, refractory) and a callout box for key takeaways.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
12
Waterfall plot and spider plot used to visualize clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
13
The slide uses a before-after comparison structure for three specific patient cases (15B-01, 15B-15, 15B-17).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
14
Includes a Kaplan-Meier plot with a table comparing historical data to VIRO-15 trial results.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Traction1 hit
15
The slide uses a cross-trial comparison to highlight the efficacy of Olvi-Vec in heavily pre-treated patients.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Market Size1 hit
16
The slide outlines a clinical trial protocol for Olvi-Vec in ovarian cancer.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
17
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
18
Includes specific patient case reports (Pt #21A-06 and Pt #21A-04) showing tumor response metrics.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
19
Includes a bio for Benny Li, PhD, CEO of Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
20
The slide highlights the strategic partnership and the division of commercial rights between Genelux and Newsoara.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
21
The slide highlights the synergy between two distinct therapeutic approaches (oncolytic immunotherapy and adoptive cell therapy).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
22
The slide uses a hub-and-spoke style layout to categorize strategic pillars.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
23
The slide uses a document-style callout for key takeaways and circular image containers for facility locations.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
24
The slide categorizes the library into therapeutic genes, immune modularity, and therapeutic antibodies.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
25
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
26
The slide uses a grid layout to present headshots, names, titles, and associated company/institution logos for each team member.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations Beat · Team1 hit
27
Includes specific financial metrics and analyst names.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
28
The slide uses a dual-track timeline approach: one for executed milestones (left) and one for future goals (right).Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
29
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
30
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
31
Genelux | Investor Presentation Deck | 37 slidesGenelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
32
The slide uses two distinct chart types to show longitudinal dynamics (line chart) and best response (waterfall chart) for the CA-125 biomarker.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
33
The slide uses a dual-axis chart to correlate tumor size (SLD) and biomarker (CA-125) response to the Olvi-Vec intervention.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
34
Includes histological images of patient samples (Pt.#15A-01 and Pt.#15A-11) showing tumor cell elimination and lymphocyte infiltration.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
35
The slide uses histology images and HALO infiltration histograms to demonstrate the mechanism of action and clinical efficacy.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
36
The slide uses a combination of immunological data (ELISPOT) and clinical imaging data (SLD) to show causality between immune response and tumor shrinkage.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
37
The slide uses clinical data (cytokine levels and PD-L1 staining) to support the mechanism of action.Genelux | Investor Presentation Deck | 37 slides · Genelux
Pitch deck Investor relations 1 hit
01
Slide 1
GMS | Results Presentation Deck | 19 slidesGMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · Attention1 hit
02
GMS | Results Presentation Deck | 19 slidesGMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · Attention1 hit
03
Includes a disclaimer regarding non-GAAP metrics at the bottom.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · Attention1 hit
04
The slide uses a four-column layout to detail strategic initiatives and recent progress for each.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
05
The slide uses a combination of summary text, callouts for specific financial impacts, and detailed tables for per-day sales and organic growth metrics.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
06
The slide uses a combination of bar charts for absolute dollar values and line charts for percentage margins.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
07
Includes footnotes detailing reconciliation and definitions.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
08
The slide uses a table to compare performance metrics across different product lines.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
09
Includes footnotes regarding reconciliation and tax rate definitions.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
10
GMS | Results Presentation Deck | 19 slidesGMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
11
Includes operational metrics like branch count and net sales per business day.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
12
Includes supplemental cash flow disclosures and a non-GAAP reconciliation for free cash flow.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
13
The table includes a footnote explaining the organic net sales growth calculation.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
14
The table includes a breakdown of adjustments (A-H) with corresponding footnotes on the right.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
15
Includes detailed line-item adjustments (A-J) with corresponding commentary.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
16
Includes footnotes A and B explaining specific adjustments.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
17
Includes a commentary section explaining the nature of the adjustments (A-E).GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
18
Includes footnotes regarding unamortized discounts and deferred financing costs.GMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
19
GMS | Results Presentation Deck | 19 slidesGMS | Results Presentation Deck | 19 slides · GMS
Conference presentation Investor relations 1 hit
01
Slide 1
Includes date and ticker symbol.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Situation & Context1 hit
02
Immix Biopharma | Investor Presentation Deck | 62 slidesImmix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Situation & Context1 hit
03
The slide uses a numbered list format to present key value propositions for investors.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Situation & Context1 hit
04
The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Situation & Context1 hit
05
The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Situation & Context1 hit